177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right ...
Sep 28, 2024 · 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a …
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Jun 23, 2021 · We conducted an international, open-label, phase 3 trial evaluating 177 Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one ...
ASCO 2025: Lutetium-177-PSMA-617 in Oligo-Metastatic Hormone …
Jun 3, 2025 · Dr. Privé concluded as follows: PSMA radioligand therapy is a promising novel treatment option for patients with oligorecurrent, hormone-sensitive prostate cancer. In this group of high-risk, …
Pluvicto (177Lu-PSMA-617): Uses in Cancer, Side Effects, Dosage ...
May 18, 2025 · The PSMAfore, a phase 3 randomized trial, published in The Lancet Oncology in 2024 evaluated [177Lu]Lu-PSMA-617 (Pluvicto) in patients with PSMA-positive metastatic castration …
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for ...
May 1, 2023 · On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane …
Study Details | NCT04689828 | 177Lu-PSMA-617 vs. Androgen …
Nov 14, 2025 · The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in …
2025 year in review: Breakthroughs in urologic oncology during a year ...
5 days ago · A major shift occurred with the FDA’s expanded indication for 177Lu-PSMA-617 (Pluvicto), now available before taxane chemotherapy for metastatic castration-resistant prostate cancer. 1 …
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer ...
May 27, 2025 · In a post-hoc analysis of circulating tumor DNA (ctDNA) features from patients with metastatic prostate cancer treated with [177Lu]Lu–PSMA-617 or cabazitaxel in the randomized …
177Lu-PSMA therapy in metastatic prostate cancer: An
Apr 1, 2024 · PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a …
177Lu-PSMA-617 versus a change of androgen receptor pathway …
Sep 28, 2024 · 177Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration …